Threshold cost-effectiveness analysis for a therapeutic vaccine against HPV-16/18-positive cervical intraepithelial neoplasia in the Netherlands

In this study, the potential price for a therapeutic vaccine against Human Papilloma Virus (HPV)-16 & 18 (pre)-malignant cervical lesions is examined. A decision tree model was built in the context of the new Dutch cervical cancer-screening program and includes a primary test for the presence of HPV. Based on data of cervical cancer screening and HPV prevalence in the Netherlands, cohorts were created with HPV-16 or 18 positive women with cervical intraepithelial neoplasia (CIN) 2 or 3 or cervical cancer stage 1A (FIGO 1A). In the base case, the vaccine price was based on equal numbers of... Mehr ...

Verfasser: Luttjeboer, Jos
Setiawan, Didik
Cao, Qi
Daemen, Toos CAHH
Postma, Maarten J.
Dokumenttyp: Artikel
Erscheinungsdatum: 2016
Reihe/Periodikum: Luttjeboer , J , Setiawan , D , Cao , Q , Daemen , T CAHH & Postma , M J 2016 , ' Threshold cost-effectiveness analysis for a therapeutic vaccine against HPV-16/18-positive cervical intraepithelial neoplasia in the Netherlands ' , Vaccine , vol. 34 , no. 50 , pp. 6381-6387 . https://doi.org/10.1016/j.vaccine.2016.10.019
Schlagwörter: Therapeutic vaccine / HPV / CIN 2/3 & FIGO 1A / Vaccine pricing / HPV DETECTION
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-29191992
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://hdl.handle.net/11370/b00d9c71-7a9a-45d5-b476-915cf500f70e